Endometrial cancer: the individual approach

Affiliations

¹ Department of Clinical Oncology, St Bartholomew's Hospital, Barts and The London NHS Trust, London EC1A 7BE, UK. Electronic address: melanie.powell10@nhs.net.

Comment

Melanie E Powell. Lancet Oncol. 2023 Mar.

. 2023 Mar;24(3):201-203.

doi: 10.1016/S1470-2045(23)00055-4. Epub 2023 Feb 14.

¹ Department of Clinical Oncology, St Bartholomew's Hospital, Barts and The London NHS Trust, London EC1A 7BE, UK. Electronic address: melanie.powell10@nhs.net.

No abstract available

Conflict of interest statement

I declare no competing interests.

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.